Gene Therapy for Ophthalmic Disorders | August 5-6 - EDT | Online

More companies than ever before are realizing the potential of gene therapies to treat a wide range of ophthalmic disorders but in practice there are still hurdles to overcome.

A variety of unique challenges must be addressed to effectively bring gene therapies to patients, from developing preclinical models that accurately translate to the clinic to validating clinical endpoints that will satisfy regulators.

Gene Therapy for Ophthalmic Disorders will virtually unite industry leaders across the ophthalmology space to overcome the specific delivery and drug development challenges faced by companies developing gene therapies for ophthalmic diseases.

Don't get left behind. Join pioneering companies including Novartis, Gensight Biologics and Spark Therapeutics to revolutionize the treatment of ophthalmic diseases.

Others Details

Brochure: https://go.evvnt.com/645519-1?pid=6581 Time: 09:00 to 17:30 Speakers: Wiley Chambers, FDA, Thierry Bordet, Eyevensys, Dan Chung, Spark Therapeutics, Viral Kansara, Clearside Biomedical Inc., Brian Mansfield, Foundation for Fighting Blindness, Adam Rogers, Hemera Biosciences, Magali Taiel, Gensight Biologics, Abraham Scaria, IVERIC bio, Samantha Vieira, Biogen, Ashley Winslow, Odylia Therapeutics, Claire Gelfman, Adverum